CN102770152B - 肽类的粘膜递送 - Google Patents

肽类的粘膜递送 Download PDF

Info

Publication number
CN102770152B
CN102770152B CN201080062361.9A CN201080062361A CN102770152B CN 102770152 B CN102770152 B CN 102770152B CN 201080062361 A CN201080062361 A CN 201080062361A CN 102770152 B CN102770152 B CN 102770152B
Authority
CN
China
Prior art keywords
peptide
active agent
mucosal delivery
peptide active
delivery composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080062361.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102770152A (zh
Inventor
保罗·博蒂
西尔维·切尔特基安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cape Suzhe Belgian Ltd By Share Ltd
Paul Botty
Original Assignee
Arisgen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arisgen SA filed Critical Arisgen SA
Publication of CN102770152A publication Critical patent/CN102770152A/zh
Application granted granted Critical
Publication of CN102770152B publication Critical patent/CN102770152B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080062361.9A 2009-11-25 2010-11-25 肽类的粘膜递送 Expired - Fee Related CN102770152B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26432409P 2009-11-25 2009-11-25
US61/264,324 2009-11-25
PCT/EP2010/068257 WO2011064316A2 (en) 2009-11-25 2010-11-25 Mucosal delivery of peptides

Publications (2)

Publication Number Publication Date
CN102770152A CN102770152A (zh) 2012-11-07
CN102770152B true CN102770152B (zh) 2016-07-06

Family

ID=44066984

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080062361.9A Expired - Fee Related CN102770152B (zh) 2009-11-25 2010-11-25 肽类的粘膜递送

Country Status (9)

Country Link
US (1) US9445992B2 (https=)
EP (1) EP2504019A2 (https=)
JP (1) JP5892940B2 (https=)
CN (1) CN102770152B (https=)
AU (1) AU2010323117B2 (https=)
BR (1) BR112012012945A2 (https=)
CA (1) CA2782056C (https=)
IL (1) IL220022A (https=)
WO (1) WO2011064316A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
US9782344B2 (en) * 2013-08-22 2017-10-10 Zp Opco, Inc. Stable glucagon peptide formulations
ES2708996T3 (es) * 2013-08-22 2019-04-12 Zp Opco Inc Formulaciones estables de péptido glucagón
US20210213096A1 (en) 2016-02-19 2021-07-15 Forschungszentrum Borstel Leibniz-Zentrum Fur Medizin Und Biowssenschaften Means and methods for treating bacterial infections
US10564140B2 (en) * 2017-04-10 2020-02-18 BUFFERAD Illinois Inc. Diffusion cell testing methods and system containing biphasic receptor fluids
CA3265745A1 (en) * 2022-08-25 2024-02-29 The University Of British Columbia Mucoadhesive pharmaceutical form for the unidirectional release of therapeutic peptidic particles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136728A2 (en) * 1983-06-29 1985-04-10 Shell Internationale Researchmaatschappij B.V. Process for the dissolution of peptides and proteins, solutions thereby obtained and their use
CN101312986A (zh) * 2005-09-28 2008-11-26 日内瓦大学 生产修饰（多）肽的方法

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2042888B (en) 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
JPS55138393A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
JPS5758615A (en) 1980-09-26 1982-04-08 Nippon Soda Co Ltd Film agnent and its preparation
JPS5770816A (en) 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
CA1208558A (en) 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4692433A (en) 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
AU565354B2 (en) 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
US5855908A (en) 1984-05-01 1999-01-05 University Of Utah Research Foundation Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
US4863737A (en) 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4671953A (en) 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US5132114A (en) 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JPH0744940B2 (ja) 1986-12-24 1995-05-17 ライオン株式会社 口腔貼付用基材
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5081157A (en) 1988-05-02 1992-01-14 Zila Pharmaceuticals, Inc. Compositions and in situ methods for forming films on body tissue
US5081158A (en) 1988-05-02 1992-01-14 Zila Pharmaceuticals, Inc. Compositions and in situ methods for forming films on body tissue
US5047244A (en) 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
JP2656338B2 (ja) 1989-01-31 1997-09-24 日東電工株式会社 口腔粘膜貼付製剤
US5750134A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US5750136A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US5298258A (en) 1989-12-28 1994-03-29 Nitto Denko Corporation Acrylic oily gel bioadhesive material and acrylic oily gel preparation
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5187154A (en) 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
JPH05238950A (ja) 1991-04-22 1993-09-17 Sanwa Kagaku Kenkyusho Co Ltd 易吸収性ｖｉｐ製剤
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
EP0788509B1 (en) 1993-08-09 2003-05-28 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Therapeutic peptide derivatives
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
CZ287945B6 (cs) 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5578315A (en) 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5639469A (en) 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
US6103226A (en) 1994-08-12 2000-08-15 Arch Development Corporation Genetically engineered cells that produce produce L. Dopa
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
CA2184316A1 (en) 1995-09-12 1997-03-13 Wei-Chi Liao Buccal delivery system for therapeutic agents
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5869082A (en) 1996-04-12 1999-02-09 Flemington Pharmaceutical Corp. Buccal, non-polar spray for nitroglycerin
EP0910339B1 (en) 1996-04-12 2005-02-02 Novadel Pharma Inc. Buccal polar spray
US5955098A (en) 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
DE59712555D1 (de) 1996-06-05 2006-04-06 Roche Diagnostics Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5686511A (en) 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US7078375B1 (en) 1996-10-25 2006-07-18 Peter Mose Larsen Diabetes-mediating proteins and therapeutic uses thereof
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US5986050A (en) 1996-12-26 1999-11-16 Poly-Med, Inc. Peracylated proteins and synthetic polypeptides and process for making the same
EP0996459B1 (en) 1997-01-07 2005-09-21 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US6723530B1 (en) 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
AU4894697A (en) 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
EA200000453A1 (ru) 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
JP2001525371A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6017545A (en) 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US7169410B1 (en) 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
ATE445006T1 (de) 1998-08-10 2009-10-15 Us Gov Health & Human Serv Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
US6193997B1 (en) 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6159931A (en) 1998-09-29 2000-12-12 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
EP1338272A1 (en) * 1998-12-21 2003-08-27 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6451286B1 (en) 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US7087215B2 (en) 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
DK1143989T3 (da) 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
NZ512663A (en) 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US6350432B1 (en) 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
US6448045B1 (en) 2000-03-10 2002-09-10 The Regents Of The University Of California Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
US6432383B1 (en) 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
ATE397938T1 (de) 2000-05-19 2008-07-15 Amylin Pharmaceuticals Inc Behandlung des akuten koronaren syndroms mit glp- 1
ATE424413T1 (de) 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
KR100508695B1 (ko) 2001-02-13 2005-08-17 한국과학기술연구원 인슐린의 경구투여용 제형과 그의 제조방법
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
EP1429731B1 (en) 2001-09-19 2007-01-03 Elan Pharma International Limited Nanoparticulate insulin formulations
US6911324B2 (en) 2001-10-18 2005-06-28 The Regents Of The University Of California Induction of beta cell differentiation in human cells
US7255102B2 (en) 2002-02-01 2007-08-14 Generex Pharmaceuticals Inc. Metered dose spray device for use with macromolecular pharmaceutical agents such as insulin
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
AU2003282955A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US7119168B2 (en) 2002-11-18 2006-10-10 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
AU2004240630B2 (en) 2003-05-15 2010-10-07 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
ATE541582T1 (de) 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
WO2007065156A2 (en) 2005-12-02 2007-06-07 Nastech Pharmaceutical Company Inc. Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
DK2100904T3 (da) 2004-04-23 2010-11-08 Conjuchem Biotechnologies Inc Fast fase til anvendelse i en fremgangsmåde til rensning af albuminkonjugater
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US7115561B2 (en) 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
US7400787B2 (en) 2005-04-07 2008-07-15 Photonic Systems, Inc. Optical modulator with coupled coplanar strip electrode and domain inversion
JP5256425B2 (ja) 2005-04-08 2013-08-07 リングアル コンセグナ ピーティーワイ エルティーディー 口腔送達システム
WO2006127361A2 (en) 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
US20090042790A1 (en) 2005-06-13 2009-02-12 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
US20090220435A1 (en) 2005-07-27 2009-09-03 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
RU2008124109A (ru) 2005-12-08 2010-01-20 МДРНА, Инк. (US) Чресслизистая доставка стабилизированных композиций эксендина
GB0601179D0 (en) 2006-01-20 2006-03-01 Univ Cambridge Tech Therapies for psychotic disorders
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
WO2007146448A1 (en) 2006-06-07 2007-12-21 Nastech Pharmaceutical Company Inc. Pharmaceutical formulations of glp-1 derivatives
WO2008016729A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
EP1905454A1 (en) 2006-09-27 2008-04-02 Paolo Botti Formulations comprising cyclic compounds
EP1972332A1 (en) * 2007-03-23 2008-09-24 BioAlliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
CN101674843A (zh) * 2007-05-01 2010-03-17 赛福伦公司 多肽的经粘膜递送组合物
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
AU2008257505B2 (en) 2007-06-01 2013-05-16 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
EP2332929A1 (en) 2009-11-25 2011-06-15 ArisGen SA Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136728A2 (en) * 1983-06-29 1985-04-10 Shell Internationale Researchmaatschappij B.V. Process for the dissolution of peptides and proteins, solutions thereby obtained and their use
CN101312986A (zh) * 2005-09-28 2008-11-26 日内瓦大学 生产修饰（多）肽的方法

Also Published As

Publication number Publication date
EP2504019A2 (en) 2012-10-03
US20120302502A1 (en) 2012-11-29
CN102770152A (zh) 2012-11-07
CA2782056A1 (en) 2011-06-03
IL220022A0 (en) 2012-07-31
AU2010323117A1 (en) 2012-06-07
US9445992B2 (en) 2016-09-20
JP5892940B2 (ja) 2016-03-23
WO2011064316A3 (en) 2012-01-05
WO2011064316A2 (en) 2011-06-03
CA2782056C (en) 2021-03-09
JP2013512226A (ja) 2013-04-11
BR112012012945A2 (pt) 2020-12-29
AU2010323117B2 (en) 2015-09-03
IL220022A (en) 2017-04-30

Similar Documents

Publication Publication Date Title
JP5628026B2 (ja) 安定した非水性薬学的組成物
US10905744B2 (en) Pharmaceutical formulations for the oral delivery of peptide drugs
US9399054B2 (en) Compositions for delivering peptide YY and PYY agonists
EP3204045B1 (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs
CN102770152B (zh) 肽类的粘膜递送
JP2010529956A5 (https=)
CN102037008A (zh) 蛋白酶稳定化的、酰化胰岛素类似物
CN110662550A (zh) 生理活性物质的口服给药
CN103347532A (zh) 口服可生物利用肽药物组合物及其方法
US20240041983A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
Youn et al. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation
WO2022268208A1 (zh) 含酰化胰岛素的药物组合物
US8895503B2 (en) Pharmaceutical composition for transnasal administration of peptide hormones or cytokines
EP3672638A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US9533048B2 (en) Mucosal delivery of drugs
AU2013205275B2 (en) Protease stabilized, acylated insulin analogues

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180919

Address after: Belgian rum

Patentee after: Cape Suzhe Belgian Limited by Share Ltd.

Address before: Weiser, Switzerland

Patentee before: Paul Botty

Effective date of registration: 20180919

Address after: Weiser, Switzerland

Patentee after: Paul Botty

Address before: Prams Batas, Switzerland

Patentee before: ARISGEN S.A.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160706

CF01 Termination of patent right due to non-payment of annual fee